Complement protein C3a enhances adaptive immune responses towards FVIII products

The most serious complication in the treatment of hemophilia A (HA) is the development of factor (F)VIII inhibitors or antidrug antibodies (ADA) occurring in 25-35% of patients with severe HA. The immunological mechanisms underlying the development of ADA against FVIII products have not been complet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringler, Eva, Iannazzo, Samira Ortega, Herzig, Jessica, Weiss, Lisa M., Anzaghe, Martina, Miller, Lilija, Waibler, Zoe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Coagulation & its Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230409/
https://www.ncbi.nlm.nih.gov/pubmed/36727395
http://dx.doi.org/10.3324/haematol.2022.281762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230409/
https://www.ncbi.nlm.nih.gov/pubmed/36727395
http://dx.doi.org/10.3324/haematol.2022.281762

Ejemplares similares